Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

NCT01578967 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma, Adult

Interventions

DRUG: Brentuximab vedotin
DRUG: ABVD

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]